TISIDB

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Multi-pass membrane protein
Domain	PF03062 MBOAT
Function	Protein-serine O-palmitoleoyltransferase that acts as a key regulator of the Wnt signaling pathway by mediating the attachment of palmitoleate, a 16-carbon monounsaturated fatty acid (C16:1), to Wnt proteins. Serine palmitoleylation of WNT proteins is required for efficient binding to frizzled receptors.

> Gene Ontology [ TOP ]
Biological Process	GO:0006497 protein lipidation GO:0009100 glycoprotein metabolic process GO:0016055 Wnt signaling pathway GO:0042157 lipoprotein metabolic process GO:0042158 lipoprotein biosynthetic process GO:0043543 protein acylation GO:0045234 protein palmitoleylation GO:0060070 canonical Wnt signaling pathway GO:0198738 cell-cell signaling by wnt
Molecular Function	GO:0016746 transferase activity, transferring acyl groups GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups GO:0017147 Wnt-protein binding GO:1990698 palmitoleoyltransferase activity
Cellular Component	GO:0008328 ionotropic glutamate receptor complex GO:0030176 integral component of endoplasmic reticulum membrane GO:0031227 intrinsic component of endoplasmic reticulum membrane GO:0032281 AMPA glutamate receptor complex GO:0034702 ion channel complex GO:0043235 receptor complex GO:0098802 plasma membrane receptor complex GO:0098878 neurotransmitter receptor complex GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04310 Wnt signaling pathway
Reactome	R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-162582: Signal Transduction R-HSA-4791275: Signaling by WNT in cancer R-HSA-195721: Signaling by Wnt R-HSA-3238698: WNT ligand biogenesis and trafficking R-HSA-5340573: WNT ligand secretion is abrogated by the PORCN inhibitor LGK974

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PORCN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between PORCN and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26041736	Melanoma	Inhibit immunity (T cell function)	We further show that the genetic silencing of the PORCN membrane-bound O-acyl transferase, which is necessary for melanoma Wnt ligand secretion, enhances antitumor T-cell immunity, and that the pharmacologic inhibition of this enzyme synergistically suppresses melanoma progression when combined with anti-CTLA-4 antibody therapy.

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PORCN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PORCN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.096	0.689
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.331	0.816
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.402	0.676
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.152	0.624
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.067	0.963
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.429	0.811
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.126	0.686
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.151	0.856
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.111	0.901
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.191	0.273
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.716	0.267
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.286	0.00643

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PORCN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PORCN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PORCN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PORCN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PORCN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PORCN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PORCN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PORCN
Name	porcupine homolog (Drosophila)
Aliases	MG61; PPN; DHOF; dermal hypoplasia, focal; FODH; probable protein-cysteine N-palmitoyltransferase porcupine; ......
Chromosomal Location	Xp11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PORCN collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PORCN